Aztreonam Shares the Same R1 Side Chain as Ceftazidime
The correct answer is C. Aztreonam. Ceftazidime, cefiderocol, and aztreonam share an identical R1 side chain, which is the primary structural determinant of allergic cross-reactivity between beta-lactam antibiotics 1.
Understanding R1 Side Chain Cross-Reactivity
The R1 side chain is the critical structural component responsible for IgE-mediated allergic cross-reactivity between penicillins and cephalosporins 2. When antibiotics share identical R1 side chains, the risk of cross-reactivity is highest in patients with documented IgE-mediated allergies.
Why This Matters Clinically
Patients with ceftazidime or cefiderocol allergy should avoid aztreonam due to the identical R1 side chain 1. The Dutch SWAB guidelines (2023) specifically recommend:
- For immediate-type reactions: Avoid aztreonam in patients with suspected ceftazidime or cefiderocol allergy 1
- For delayed-type reactions: Avoid aztreonam when the index reaction occurred <1 year ago 1
Conversely, aztreonam can be safely used in patients allergic to other cephalosporins (those without the shared R1 side chain), as minimal cross-reactivity has been observed 1.
Why the Other Options Are Incorrect
- Amoxicillin (A): Shares R1 side chains with ampicillin, cephalexin, cefaclor, and cefadroxil—not with ceftazidime 2
- Cephalexin (B): Shares R1 side chains with amoxicillin, ampicillin, cefaclor, and cefadroxil—not with ceftazidime 2
- Linezolid (D): An oxazolidinone antibiotic with no structural relationship to beta-lactams; has no R1 side chain
Clinical Pitfall to Avoid
The historical belief that aztreonam (a monobactam) is universally safe in all beta-lactam allergies is incorrect. While aztreonam generally shows minimal cross-reactivity with most penicillins and cephalosporins due to its unique monobactam structure, the shared R1 side chain with ceftazidime creates a specific exception to this rule 1.